CS

Champions Oncology IncNASDAQ CSBR Stock Report

Last reporting period 31 Jul, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.064

Micro

Exchange

XNAS - Nasdaq

CSBR Stock Analysis

CS

Uncovered

Champions Oncology Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-42/100

Low score

Market cap $B

0.064

Dividend yield

Shares outstanding

13.559 B

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 230 full-time employees. The firm's research center operates in both regulatory and non-regulatory environments and consists of a set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverages the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

View Section: Eyestock Rating